Terri Parker

Hematologist and clinical researcher focusing on AL amyloidosis, leading the SWOG S1702 phase 2 trial evaluating isatuximab in relapsed/refractory AL amyloidosis with notable hematologic and organ responses.

Best podcasts with Terri Parker

Ranked by the Snipd community

Nov 20, 2025 • 15min

Advancing Blood Disorder Treatments Through Precision Therapeutics

Terri Parker is a hematologist and clinical researcher focusing on AL amyloidosis, while Peter Lenting specializes in bleeding disorders. They discuss groundbreaking advancements in treatments for these conditions. Parker reveals impressive results from a phase 2 trial using isatuximab in AL amyloidosis, showcasing a 77% hematologic response. Meanwhile, Lenting shares his innovative work on a bispecific nanobody designed to extend the half-life of von Willebrand factor, potentially transforming care for patients with type 1 VWD.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app